Foss-Freitas, Maria C.
Akinci, Baris
Neidert, Adam
Bartlett, Victoria J.
Hurh, Eunju
Karwatowska-Prokopczuk, Ewa
Oral, Elif A.
Funding for this research was provided by:
akcea therapeutics (Not Applicable)
Article History
Received: 28 July 2021
Accepted: 27 October 2021
First Online: 5 December 2021
Declarations
:
: EAO has received grant support from Aegerion Pharmaceuticals, Akcea Therapeutics, Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Gemphire Therapeutics, Rhythm Pharmaceuticals, and GI Dynamics. She also served as an advisor to the first 5 companies. BA has attended Scientific Advisory Board Meetings organized by Aegerion Pharmaceuticals and Regeneron Pharmaceuticals and has received honoraria as a speaker from AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. VJB, EH and EKP work at Akcea Therapeutics Inc. Other authors declare no conflicts of interest.